Table 1.
Characteristics of the studies included in meta-analysis.
| References | Country | Blood sample | Study design | Case/control, number | Assay method and resource | Assay resource | Total resistin means (ng/mL) and SD |
|---|---|---|---|---|---|---|---|
| Kumor et al. 2009 [24] | Poland | Serum | Case-control | 36/25 | ELISA | R&D Systems | 6.79 ± 2.41/3.6 ± 1.08 |
| Gonullu et al. 2010 [26] | Turkey | Serum | Case-control | 36/37 | ELISA | BioSource | 6.1 ± 3.3/4.5 ± 1.5 |
| Nakajima et al. 2010 [23] | Japan | Plasma | Case-control | 115/115 | ELISA | BioVender Laboratory Medicine | 4.5 (3.1–6.4)/3.1 (2.2–4.7)a |
| Danese et al. 2012 [27] | Italy | Serum | Case-control | 40/40 | ELISA | Mediagnost | 5.88 (1.84–22.35)/4.94 (1.82–8.16)b |
| Hillenbrand et al. 2012 [32] | Germany | Plasma | Case-control | 67/60 | Multiplex immunoassay | Millipore | 10.9 (4.2–43.5)/10.8 (5.2–24.9)b |
| Ho et al. 2012 [31] | USA | Plasma | Case-cohort | 456/834 | Multiplex immunoassay | Millipore | 12.8 (9.9–16.4)/12.3 (9.8–15.6)a |
| Joshi et al. 2014 [18] | South Korea | Serum | Case-control | 100/100 | ELISA kit | Adipogen | 4.9 ± 2.3/2.8 ± 1.7 |
| Lu et al. 2010 [28] | China | Serum | Case-control | 30/30 | ELISA | ADL | 7.72 ± 2.6/7.42 ± 3.72 |
| Tulubas et al. 2014 [21] | Turkey | Serum | Case-control | 30/30 | ELISA | AssayMax ELISA kit | 18.77 ± 5.09/13.36 ± 6.36 |
| Wägsäter et al. 2008 [29] | Sweden | Plasma | Case-control | 35/34 | ELISA | R&D Systems | 3.95 (1.50–2.40)/5.25 (2.00–3.00)b |
| Kosova et al. 2013 [25] | Turkey | Serum | Case-control | 20/20 | ELISA | Millipore Corporation | 4.92 ± 2.2/3.39 ± 1.1 |
aMedian (interquartile range).
bMedia (range).